Medicinal Genomics is pioneering the genomics of medical cannabis and hemp. In 2011, Medicinal Genomics made worldwide headlines for being the first group to decode the Cannabis Genome. An increasing amount of scientific evidence supports the theory that cannabinoid compounds may have numerous medical benefits. Medicinal Genomics has the largestDNA sequence database of the cannabis plant and is well-positioned to design fingerprinting assays for strain genotyping and sequencing services for strain development. In 2011, Medicinal Genomics was acquired by Courtagen Life Sciences, Inc.

Biotechnology

Cannabis

Health Care

Medicinal Genomics

Brendan M.

Stephen McLaughlin

Stephen Dailey

Nicholas Lawson

Nathan Houde

Yvonne Helbert

Randi Tarricone

Liam K.

Juliana Sillva

Timothy Olcott

Sherman Hom

Rich Upton

Douglas K.

David Rapisarda

Daniel Walsh

Benjamin Amirault

The Leadership Team at Medicinal Genomics is responsible for setting the strategic vision and operational direction of the company. Comprising high-level executives, including the CEO, SVP of Operations, VP of Sales, and the Managing Director of Cannmed Events, this team oversees company-wide initiatives, drives sales growth, and coordinates major events and partnerships, all while ensuring the company's pioneering work in cannabis genomics aligns with market demands and scientific advancements.

Leadership Team

Sales and Customer Support

Scientific Team

Leadership Team

About

Team members

Other teams at Medicinal Genomics

Sales and Customer Support

Scientific Team